TY - JOUR
T1 - Verification of the performance of the BD MAX Check-Points CPO Assay on clinical isolates
AU - Chung, Hae Sun
AU - Lee, Miae
N1 - Funding Information:
Research funding: This work was supported by Ewha Womans University Research Grant of 2016 and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2017R1C1B5017422). The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Publisher Copyright:
© 2020 2020 Hae-Sun Chung et al., published by De Gruyter, Berlin/Boston.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - The BD MAX Check-Points CPO Assay (BD MAX CPO Assay; BD, The Netherlands) is a diagnostic test designed for the rapid detection and differentiation of the blaKPC, blaNDM, blaVIM/blaIMP-1, and blaOXA-48 genes. We verified the performance of the BD MAX CPO Assay to implement it in the clinical laboratory. A total of 113 bacterial isolates collected from various clinical specimens harboring carbapenemase genes as confirmed by polymerase chain reaction (PCR) and sequencing were evaluated. The results of the BD MAX CPO Assay were compared to previously confirmed results. All results of the BD MAX CPO Assay were concordant with previous results; 61 Klebsiella pneumoniae carbapenemase (KPC), 40 New Delhi metallo-β-lactamase (NDM), three oxacillinase-48 (OXA-48)-like, two imipenem (IMP), and four multiple carbapenemase genes (one KPC/NDM, three NDM/OXA) were detected by the BD MAX CPO Assay. Three non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae isolates were negative. The BD MAX CPO Assay can be used to identify carbapenemase gene in bacterial isolates cultured from clinical specimens in the clinical laboratory.
AB - The BD MAX Check-Points CPO Assay (BD MAX CPO Assay; BD, The Netherlands) is a diagnostic test designed for the rapid detection and differentiation of the blaKPC, blaNDM, blaVIM/blaIMP-1, and blaOXA-48 genes. We verified the performance of the BD MAX CPO Assay to implement it in the clinical laboratory. A total of 113 bacterial isolates collected from various clinical specimens harboring carbapenemase genes as confirmed by polymerase chain reaction (PCR) and sequencing were evaluated. The results of the BD MAX CPO Assay were compared to previously confirmed results. All results of the BD MAX CPO Assay were concordant with previous results; 61 Klebsiella pneumoniae carbapenemase (KPC), 40 New Delhi metallo-β-lactamase (NDM), three oxacillinase-48 (OXA-48)-like, two imipenem (IMP), and four multiple carbapenemase genes (one KPC/NDM, three NDM/OXA) were detected by the BD MAX CPO Assay. Three non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae isolates were negative. The BD MAX CPO Assay can be used to identify carbapenemase gene in bacterial isolates cultured from clinical specimens in the clinical laboratory.
KW - BD MAX Check-Points CPO Assay
KW - carbapenemase
KW - Enterobacteriaceae
KW - real-time PCR
UR - http://www.scopus.com/inward/record.url?scp=85085076628&partnerID=8YFLogxK
U2 - 10.1515/labmed-2019-0145
DO - 10.1515/labmed-2019-0145
M3 - Article
AN - SCOPUS:85085076628
SN - 2567-9430
VL - 44
SP - 165
EP - 168
JO - Journal of Laboratory Medicine
JF - Journal of Laboratory Medicine
IS - 3
ER -